ALNY ALNYLAM PHARMACEUTICALS INC
2026Q1 · CUSIP 02043Q107 · Sector: Healthcare & Biotech
Danger · Dual-confirm: breadth + price
Holders
779
Δ holders QoQ
-67
Breadth percentile
Top 98%
Whale holders
286
Δ whales
-8
Inst. holding value
$40.4B
New positions
102
Closed positions
169
Price momentum (1Q)
-13.9%
Put / Call
17/17
Breadth history (34 quarters)
Past Lit Events & Aftermath 14 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2025Q4 | Top 17% | -13.9% | — |
| 2025Q3 | Top 1% | -26.3% | -35.2% |
| 2025Q2 | Top 11% | -1.7% | -27.2% |
| 2025Q1 | Top 6% | +57.0% | +57.8% |
| 2024Q4 | Top 16% | +16.7% | +83.3% |
| 2024Q3 | Top 6% | +7.9% | +24.4% |
| 2024Q2 | Top 8% | -3.9% | -6.6% |
| 2023Q4 | Top 10% | +1.6% | +86.7% |
Options Sentiment
Put holders
17
QoQ: -6
Call holders
17
QoQ: -4
See methodology →
Fundamentals
PE (TTM)
117.0
EPS (TTM)
$2.33
EPS YoY
—
Revenue (TTM)
$3.7B
Revenue YoY
+65.2%
Net margin
8.5%
ROE
39.8%
Debt ratio
84.1%
FCF (TTM)
$465M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
P/E (TTM) over time
P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden
As of 2025-12-31 · SEC filings (XBRL)
Get the next update
2026Q2 holdings publish around Aug 15 — subscribe to receive the lists first.